Skip to main content

Table 1 Demographic data

From: Specific immunotherapy ameliorates ulcerative colitis

Characteristic

Placebo

SIT

CB

SIT/CB

(N = 22)

(N = 23)

(N = 25)

(N = 26)

Age (years)

43.5 ± 11.2

41.8 ± 12.5

42.2 ± 8.6

43.3 ± 10.7

Male-no. (%)

12 (54.5)

11 (47.8)

14 (56)

14 (53.8)

Body weight (kg)

62.3 ± 11.5

61.4 ± 12.6

60.8 ± 14.1

61.8 ± 10.9

Current smoker-no. (%)

4 (18.2)

3 (13)

2 (8)

3 (11.5)

Duration of disease (years)

6.2 ± 5.2

5.8 ± 6.1

6.3 ± 4.9

6.3 ± 5.4

Mayo clinic score (MCS)

8.5 ± 1.2

8.6 ± 1.8

8.6 ± 1.1

8.6 ± 1.6

Partial MCS

6.1 ± 1.1

6.0 ± 1.4

6.1 ± 1.4

6.0 ± 1.5

IBDQ score

125 ± 36

126 ± 32

123 ± 33

125 ± 30

Fecal calprotectin (mg/g)

1.2 ± 1.1

1.1 ± 0.9

1.2 ± 0.8

1.1 ± 0.8

Site of disease-no. (%)

 Rectum and sigmoid colon

4 (18.2)

6 (27.3)

5 (20)

6 (23.1)

 Left side of colon

6 (27.3)

6 (27.3)

8 (32)

6 (23.1)

 Proximal colon

7 (31.8)

5 (21.7)

3 (8)

5 (19.2)

 All of the colon

5 (22.7)

6 (27.3)

9 (36)

9 (34.6)

Medication-no. (%)

 Steroids

3 (13.6)

4 (17.4)

5 (20)

7 (26.9)

 Immunosuppressor

7 (31.8)

5 (21.7)

7 (28)

6 (23.1)

 Steroids/immunosuppressor

6 (27.3)

5 (21.7)

7 (28)

7 (26.9)

 No medication

6 (27.3)

9 (39.1)

6 (24)

6 (23.1)

Fecal calprotectin

 Before

255.6 (38.6)

266.8 (42.5)

249.5 (41.3)

253.8 (39.5)

 After

244.8 (36.8)

258.3 (41.7)

241.5 (39.5)

68.3 (8.5)*

Hemoglobin (g/l)

 Before

122.5 ± 15.8

123.8 ± 17.6

125.6 ± 15.2

122.8 ± 14.5

 After

124.3 ± 14.2

123.1 ± 13.6

125.2 ± 11.5

144.6 ± 11.1*

WBC (×10−9/l)

 Before

8.6 ± 3.2

8.6 ± 3.5

8.6 ± 3.2

8.5 ± 3.6

 After

8.3 ± 2.5

8.2 ± 4.1

8.2 ± 2.4

6.1 ± 1.4*

  1. WBC white blood cell count, Before before treatment, After after treatment
  2. * p < 0.01, compared with the results before treatment in the same group